james s. welsh, ms, md northern illinois university

125
THE ABSCOPAL EFFECT, CONTAGIOUS CANCERS, TRANSPLANTED CANCERS AND PREGNANCY: CLUES TO A GENUINE CURE FOR CANCER? James S. Welsh, MS, MD Northern Illinois University

Upload: ivana

Post on 23-Feb-2016

22 views

Category:

Documents


0 download

DESCRIPTION

James S. Welsh, MS, MD Northern Illinois University. the Abscopal Effect, Contagious Cancers, Transplanted Cancers and Pregnancy: Clues to a genuine Cure for cancer?. Curious clues. Contagious cancers – should not occur Transplanted cancers – should not thrive - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: James S. Welsh, MS, MD  Northern Illinois University

THE ABSCOPAL EFFECT, CONTAGIOUS CANCERS,

TRANSPLANTED CANCERS AND PREGNANCY:

CLUES TO A GENUINE CURE FOR CANCER?

James S. Welsh, MS, MD Northern Illinois University

Page 2: James S. Welsh, MS, MD  Northern Illinois University

Curious clues Contagious cancers – should not occur Transplanted cancers – should not thrive Surrogate pregnancies – should not be

possible Gestational trophoblastic neoplasia –

should not exist

Page 3: James S. Welsh, MS, MD  Northern Illinois University

Curious clues Contagious cancers – should not occur Transplanted cancers – should not thrive Surrogate pregnancies – should not be

possible Gestational trophoblastic neoplasia –

should not exist And one more thing that should not

happen…

Page 4: James S. Welsh, MS, MD  Northern Illinois University

A sad story Young male in his 30’s with widespread

metastatic melanoma Metastases to lung, liver, lymph node and

bone Life expectancy ~4 months(?) Severe pain in hip Hypofractionated course of photon-based

external beam radiotherapy

Page 5: James S. Welsh, MS, MD  Northern Illinois University

A sad story Young male in his 30’s with widespread

metastatic melanoma Metastases to lung, liver, lymph node and

bone Life expectancy ~4 months(?) Severe pain in hip Hypofractionated course of photon-based

external beam radiotherapy Within 4 months ALL evidence of cancer was

completely gone!

Page 6: James S. Welsh, MS, MD  Northern Illinois University

A man’s aggressive cancer mysteriously disappears as quickly as it arrived. Pick up the issue and enjoy the adventure”

Page 7: James S. Welsh, MS, MD  Northern Illinois University

“THE ABSCOPAL PHENOMENON: Anti-cancer action at a distance – Oncology’s equivalent to quantum entanglement”

Page 8: James S. Welsh, MS, MD  Northern Illinois University

“Disappearing Act”

Page 9: James S. Welsh, MS, MD  Northern Illinois University

The Abscopal Effect So why is this sad????

Page 10: James S. Welsh, MS, MD  Northern Illinois University

The Abscopal Effect So why is this sad???? One of only two encounters with this… Pursuit of the underlying mechanism

and the ability to do it again at will has become an obsession…

Page 11: James S. Welsh, MS, MD  Northern Illinois University

So where does one begin the search???

Page 12: James S. Welsh, MS, MD  Northern Illinois University

So where does one begin the search???

Page 13: James S. Welsh, MS, MD  Northern Illinois University
Page 14: James S. Welsh, MS, MD  Northern Illinois University
Page 15: James S. Welsh, MS, MD  Northern Illinois University
Page 16: James S. Welsh, MS, MD  Northern Illinois University
Page 17: James S. Welsh, MS, MD  Northern Illinois University
Page 18: James S. Welsh, MS, MD  Northern Illinois University
Page 19: James S. Welsh, MS, MD  Northern Illinois University

Devil Facial Tumor Disease

First observed in 1996 DFTD is a contagious cancer

Tumor cells directly transplanted from one animal to another

A xenograft Typically causes death within 6-18 months Species is threatened with extinction

Page 20: James S. Welsh, MS, MD  Northern Illinois University

Cytogenetic proofa. Normal karyotype (14 chromosomes,

including XY)b, Karyotype of cancer cells

Page 21: James S. Welsh, MS, MD  Northern Illinois University

Devil Facial Tumor Disease

But if it’s a “transplanted organ” shouldn’t it be rejected???

Page 22: James S. Welsh, MS, MD  Northern Illinois University

Devil Facial Tumor Disease

But if it’s a “transplanted organ” shouldn’t it be rejected???

Do I have to be extra careful in the clinic when doing procedures?

Are there any other examples of this in the animal kingdom?

Page 23: James S. Welsh, MS, MD  Northern Illinois University
Page 24: James S. Welsh, MS, MD  Northern Illinois University
Page 25: James S. Welsh, MS, MD  Northern Illinois University

Canine Transmissible Venereal Tumor(CTVT)

“Sticker’s sarcoma”

Page 26: James S. Welsh, MS, MD  Northern Illinois University

Canine Transmissible Venereal Tumor

In immunologically compromised dogsthe tumor progresses, ulcerates, metastasizes

and kills the dog But in most dogs the tumors spontaneously

regress after a period of logarithmic growth Immunity develops and prevents successive

occurrences

Page 27: James S. Welsh, MS, MD  Northern Illinois University

Molecular clock data suggest an ancient origin

Page 28: James S. Welsh, MS, MD  Northern Illinois University

How has CTVT survived for so long???

CTVT has a unique trick to fool the immune system – but eventually the immune system gets wise and awakens

Clonally transmissible cancers in dogs and Tasmanian devilsE P Murchison. Oncogene. 2008 Dec;27 Suppl 2:S19-30

Page 29: James S. Welsh, MS, MD  Northern Illinois University

Immunological mechanisms of escape in canine transmissible venereal tumor

CTVT cells initially reduce their expression of MHC Class I moleculesreduces visibility to the host's immune system

MHC Class I downregulation allows it to escape adaptive immunity (T-cell–mediated immunity)(which would occur if MHC I were fully expressed)

This trick also allows escape from innate immunity (natural killer cells)(which would eradicate any cells completely devoid of

MHC I)

Page 30: James S. Welsh, MS, MD  Northern Illinois University

Some have proposed that the primary reason DFTD exists is because of the lack of genetic diversity in the population

All Tasmanian devils are closely related and so organ transplants would not be readily rejected

Immunological mechanisms of escape in devil facial tumor disease

Page 31: James S. Welsh, MS, MD  Northern Illinois University

Some have proposed that the primary reason DFTD exists is because of the lack of genetic diversity in the population

All Tasmanian devils are closely related and so organ transplants would not be readily rejected

Well, I REJECT THIS HYPOTHESIS!

Immunological mechanisms of escape in devil facial tumor disease

Page 32: James S. Welsh, MS, MD  Northern Illinois University

Some have proposed that the primary reason DFTD exists is because of the lack of genetic diversity in the population

All Tasmanian devils are closely related and so organ transplants would not be readily rejected

Well, I REJECT THIS HYPOTHESIS! These tumors are grossly, histologically,

cytogenetically and molecularly VERY different from any living Tasmanian devil…There is something else going on

Immunological mechanisms of escape in devil facial tumor disease

Page 33: James S. Welsh, MS, MD  Northern Illinois University

The future of DFTD and the Tasmanian devil???

Will the devil (and the disease) go extinct?

Will natural selection (in the cancer) create a less virulent tumor that doesn’t kill all its hosts???This may be what happened with the dog tumor

Will natural selection (in the Tasmanian devil) create a kinder, gentler devil The “Tasmanian Angel”?

Page 34: James S. Welsh, MS, MD  Northern Illinois University

The Tasmanian Angel

Page 35: James S. Welsh, MS, MD  Northern Illinois University

Similarities and Differences: A biologist’s perspective

Both are rare (extremely rare) examples of a contagious cancer

Both can be thought of as transplanted parasites

DFTD emerged recently and is highly virulent CTVT probably arose thousands of years

ago but typically does NOT kill its host One is lethal, the other has evolved to survive

with its host

Page 36: James S. Welsh, MS, MD  Northern Illinois University

Similarities and Differences: A physician’s perspective

Page 37: James S. Welsh, MS, MD  Northern Illinois University

One is relentlessly progressive and uniformly fatal

The other spontaneously regresses Thus one behaves like most human

cancers while the other behaves like what we wish human cancers would do…

How can we force human cancers to behave like dogs rather than devils???Devil dog transition

Similarities and Differences: A physician’s perspective

Page 38: James S. Welsh, MS, MD  Northern Illinois University

Another line of reasoning…

Suppose an organ or tissue is intentionally or accidentally transferred to another person?

What usually happens in Man?

Page 39: James S. Welsh, MS, MD  Northern Illinois University

Organ transplants Organ transplantation requires a high

degree of genetic similarities (“a match”) Even with a good match, chronic

immunosupression is required Without immunosupression poor matches

(and even good ones) are vigorously rejected

So what about cancer?

Page 40: James S. Welsh, MS, MD  Northern Illinois University

What about an accidentally transplanted cancer?

Man Gets Woman's Cancer from Kidney Transplant - CBS News (May 2010) “... The scenario was unique…. A man had gotten a

transplanted kidney from a woman who had uterine cancer and didn't know it…”

He died of cancer only seven months after receiving the transplant

Page 41: James S. Welsh, MS, MD  Northern Illinois University

How can this happen??!?! One might expect cancer to be rejected Does the necessary immunosupression

impede the rejection process?

“Contaminated” vital organ transplants (heart , lung and liver) are almost always rapidly fatal

What about non-vital organs???

Page 42: James S. Welsh, MS, MD  Northern Illinois University

Renal transplants Kidneys are not completely indispensible Immunosupression could be halted Kidney (and cancer) should be rejected Kidney can be removed Patient could be put on dialysis and given

another kidney This is what often happens

Page 43: James S. Welsh, MS, MD  Northern Illinois University

Renal transplants Kidneys are not completely indispensible Immunosupression could be halted Kidney (and cancer) should be rejected Kidney can be removed Patient could be put on dialysis and given

another kidney This is what often happens But not always….

Page 44: James S. Welsh, MS, MD  Northern Illinois University

Example of kidney being rejected while the cancerous cargo is left

unmolested!!!

Strauss and Thomas. Lancet Oncol 2010; 11: 790–96

Page 45: James S. Welsh, MS, MD  Northern Illinois University

Melanoma has been transferred through organ donation up to 32 yrs after treatment!Suggests that cancer can remain dormant for

decades (maybe forever?)But can be reactivated upon transplantation into a

recipient1.) The immune system must be keeping these cancer

cells in check in the donor2.) The recipient’s immunosuppression is NOT the only

reason why the cancer can redevelop3.) The fact that a transplanted cancer can thrive

unmolested in the recipient suggests it has some form of “invisibility” to the immune system

Page 46: James S. Welsh, MS, MD  Northern Illinois University

Is there another example where something is completely untouched

by the immune system?

Page 47: James S. Welsh, MS, MD  Northern Illinois University

Is there another example where something is completely untouched

by the immune system? Yes of course For survival of the species…

Page 48: James S. Welsh, MS, MD  Northern Illinois University

Is there another example where something is completely untouched

by the immune system? Yes of course For survival of the species… Pregnancy is normally given complete

sanctuary from the immune system

Page 49: James S. Welsh, MS, MD  Northern Illinois University

How profound is the suppression of the immune response in pregnancy?

Extreme! First, mother and embryo/fetus are only

half-related (semiallogeneic)

Page 50: James S. Welsh, MS, MD  Northern Illinois University

Extreme! First, mother and embryo/fetus are only

half-related (semiallogeneic) Second, surrogate mothers who are not

related at all are possible - no genetic relationship at all to embryo

How profound is the suppression of the immune response in pregnancy?

Page 51: James S. Welsh, MS, MD  Northern Illinois University

Extreme! First, mother and embryo/fetus are only

half-related (semiallogeneic) Second, surrogate mothers who are not

related at all are possible - no genetic relationship at all to embryo

Finally, surrogate mothers of DIFFERENT SPECIES are sometimes possible!

How profound is the suppression of the immune response in pregnancy?

Page 52: James S. Welsh, MS, MD  Northern Illinois University

Fig. 1. River buffalo (2n = 50) calf born from swamp buffalo (2n = 48) surrogate mother after non-surgical transfer of vitrified in vitro-derived embryo.Danilda Hufana-Duran, Prudencio B. Pedro, Hernando V. Venturina, Peregrino G. Duran, Libertado C. Cruz. Full-term delivery of river buffalo calves (2n = 50) from in vitro-derived vitrified embryos by swamp buffalo recipients (2n = 48) Livestock Science, Volume 107, Issues 2–3, April 2007, Pages 213-219

Page 53: James S. Welsh, MS, MD  Northern Illinois University
Page 54: James S. Welsh, MS, MD  Northern Illinois University

Is the womb (uterus) the key to this immune sanctuary?

Page 55: James S. Welsh, MS, MD  Northern Illinois University

Is the womb (uterus) the key to this immune sanctuary?

Ectopic pregnancies occur outside the womb…

Page 56: James S. Welsh, MS, MD  Northern Illinois University

Is the womb (uterus) the key to this immune sanctuary?

Ectopic pregnancies occur outside the womb…

Therefore the uterine endometrium cannot be the answer!

Page 57: James S. Welsh, MS, MD  Northern Illinois University

A surgical emergency

Page 58: James S. Welsh, MS, MD  Northern Illinois University
Page 59: James S. Welsh, MS, MD  Northern Illinois University
Page 60: James S. Welsh, MS, MD  Northern Illinois University
Page 61: James S. Welsh, MS, MD  Northern Illinois University

So the embryo’s “immunity from immunity” is quite profound

Embryos are normal; cancer is not! Maybe this immune sanctuary is granted

only to normal embryos?

Page 62: James S. Welsh, MS, MD  Northern Illinois University

Gestational trophoblastic disease

Anything but normal…

Rather than the zygote developing into an embryo and fetus, it develops into a grape-like mass

Hydatidiform mole (molar pregnancy)

Page 63: James S. Welsh, MS, MD  Northern Illinois University
Page 65: James S. Welsh, MS, MD  Northern Illinois University
Page 66: James S. Welsh, MS, MD  Northern Illinois University
Page 67: James S. Welsh, MS, MD  Northern Illinois University

Gestational trophoblastic disease Three different degrees of severity:

Hydatidiform molesInvasive molesChoriocarcinoma – extremely rapidly growing

and potentially lethal cancer

Often the chromosomes are completely from the father – i.e. the cancer is strictly paternal (foreign) in origin

ABSOLUTELY should be rejected!!!

Page 68: James S. Welsh, MS, MD  Northern Illinois University

Cancer and pregnancy DO share features enabling them to evade the immune system

The analogies are more obvious when examining clinical tumor markers

Page 69: James S. Welsh, MS, MD  Northern Illinois University

Tumor markers Carcinoembryonic antigen

Colon/rectum cancer, pancreas, breast, ovary, or lung

Alpha Feto-proteinIncreased during pregnancy in cases of spina bifida

and other fetal malformationsLower than normal in Down syndromeTesticular cancer and Hepatocellular carcinoma

Human chorionic gonadotropinThe pregnancy testGerm cell tumors, testicular cancers,

neuroendocrine islet cell tumors

Page 70: James S. Welsh, MS, MD  Northern Illinois University

Cancer and pregnancy use the same ‘cloaking device'

Cancer evades the immune system ---- by masquerading as a baby!

But how can we expose the cancer for what it is?

Page 71: James S. Welsh, MS, MD  Northern Illinois University
Page 72: James S. Welsh, MS, MD  Northern Illinois University

Dr. William B. Coley (1862-1936) Developed Coley’s toxin in 1893

“… with a degree of success…”“…afforded some therapeutic successes…”

Page 73: James S. Welsh, MS, MD  Northern Illinois University

The curious case of Mr Stein… Recurrent sarcoma despite four operations Erysipelas (an infection with Streptococcus

pyogenes) But supposedly his cancer regressed during

the life-threatening infection…

Where did Coley get his idea?

Page 74: James S. Welsh, MS, MD  Northern Illinois University

Where did Coley get his idea?

The curious case of Mr Stein… Recurrent sarcoma despite four operations Erysipelas (an infection with Streptococcus

pyogenes) But supposedly his cancer regressed during

the life-threatening infection…

Found by Coley in the lower East Side ghetto six years later — in the best of health

Page 75: James S. Welsh, MS, MD  Northern Illinois University

Coley’s toxins Surmised that the infection had stimulated

Mr Stein’s immune system this immune reaction eradicated the cancer

Began to intentionally give patients infections to “awaken” their immune systems

Moved to a safer strategy of killed bacteria (Streptococcus pyogenes and Serratia marcescens)

Page 76: James S. Welsh, MS, MD  Northern Illinois University

Coley’s first patients January 1893 - John Ficken: bedridden, with a

massive, inoperable abdominal sarcoma Vaccine injected right into tumor every few days Dramatic fevers and chills Tumor gradually shrank

After 4 months the tumor was 1/5 its original sizeBy August, the tumor was barely perceptible

The patient was apparently cured Lived another 26 yrs

Page 77: James S. Welsh, MS, MD  Northern Illinois University
Page 78: James S. Welsh, MS, MD  Northern Illinois University

Immunotherapy’s Dark Ages

Coley died in 1936 and his treatment disappeared along with him

(Note entirely in the veterinary community however…)

Page 79: James S. Welsh, MS, MD  Northern Illinois University

Coley’s legacy and Immunotherapy’s Renaissance Bacterial lipopolysaccharide-induced

secretion of tumor necrosis factor-a (TNFa)

1.) Can we make vaccines to cancer?2.) Can we use other immune strategies such

as direct administration of TNF, interferons, interleukins, etc?

Page 80: James S. Welsh, MS, MD  Northern Illinois University

Two Branches of The Human Immune System

The Innate response - Non-specific, first line of defense Proteins (for example, complement) and Cells (for example, natural killer cells and neutrophils)

The Adaptive response Highly specific Capable of responding to new antigensPossesses a “memory” Antibodies from B-cells and T cell mediated immunity

Estimated that gene rearrangements can yield ~5x1013 different Ig molecules and 1018 different TCRs(!)

Page 81: James S. Welsh, MS, MD  Northern Illinois University
Page 82: James S. Welsh, MS, MD  Northern Illinois University
Page 83: James S. Welsh, MS, MD  Northern Illinois University

Cancer Immunotherapy I Interferon Interleukins Vaccines Adoptive T cell therapy

LAKs, TILs

Page 84: James S. Welsh, MS, MD  Northern Illinois University

Cancer Immunotherapy I Only modest success Toxic treatment WHY???

Page 85: James S. Welsh, MS, MD  Northern Illinois University

Cancer Immunotherapy I Only modest success Toxic treatment WHY???

To attempt to answer this, let’s return to the analogy with pregnancy

Page 86: James S. Welsh, MS, MD  Northern Illinois University

How is the placenta, embryo and fetus protected?

Regulatory T cells (Treg cells)CD4+/CD25+/FOXP3+

Increase during pregnancy Conversely, diminished numbers are associated

with spontaneous abortions i.e. immunological rejection of the fetus

Spontaneous abortions in mice can be prevented by transferring Tregs into abortion-prone animalsA possible explanation for infertility and A possible means of reducing miscarriage???

Page 87: James S. Welsh, MS, MD  Northern Illinois University

How is the placenta, embryo and fetus protected?

Treg cells prevent fetal rejection by creating a tolerant microenvironment characterized by high levels of:

TGF-β, IL-10, LIF, and HO-1

Page 88: James S. Welsh, MS, MD  Northern Illinois University

How is the placenta, embryo and fetus protected?

Treg cells prevent fetal rejection by creating a tolerant microenvironment characterized by high levels of:

TGF-β, IL-10, LIF, and HO-1

TGF-β is elaborated by tumors! And Tregs are abundant in tumors! A “bizarre tumor microenvironment” Is this why cancer immunotherapy failed in the

past?

Page 89: James S. Welsh, MS, MD  Northern Illinois University

Why previous immunotherapy approaches have failed

Maybe vaccines and cytokines turn on both a “tumor kill” pathway AND a “tumor protect” pathway

Both arms strengthened Thus, there is no net gain

Page 90: James S. Welsh, MS, MD  Northern Illinois University

Not enough of a good thing paradigm

(ineffective tumor-kill pathway)

Page 91: James S. Welsh, MS, MD  Northern Illinois University

Too much of a bad thing paradigm (too powerful “tumor-

protect” pathway)

Page 92: James S. Welsh, MS, MD  Northern Illinois University

TOLERANCE : How tumors escape immunity (i.e. what REALLY happens vs what we

thought was happening)

Page 93: James S. Welsh, MS, MD  Northern Illinois University

The tumor microenvironment

Lymphocytes infiltrating the tumor: Regulatory T cells Tumor associated macrophages: “M2 responses” Dendritic cells: Impaired/immature Myeloid-derived suppressor cells (MDSCs) Cancer associated fibroblasts: Secrete TGF-β and

VEGF, FGFs, PDGF to induce angiogenesis Elevated levels of neutrophils

Depress T-cells, stimulate tumor vasculature, promote tumor invasion

Rather than a half-life of <1day, in the tumor microenvironment they live much longer

Page 94: James S. Welsh, MS, MD  Northern Illinois University
Page 95: James S. Welsh, MS, MD  Northern Illinois University

Can modern tumor immunobiology translate into effective cancer

immunotherapy? Overcoming checkpoint interference Some steps have negative feedback loops

(“checkpoints”)tumors exploit checkpoints

Each exploited checkpoint might represent a therapeutic avenue

Page 96: James S. Welsh, MS, MD  Northern Illinois University
Page 97: James S. Welsh, MS, MD  Northern Illinois University
Page 98: James S. Welsh, MS, MD  Northern Illinois University

T-Cell Activation and Expansion

Page 99: James S. Welsh, MS, MD  Northern Illinois University

The “Immunological Synapse”

Page 100: James S. Welsh, MS, MD  Northern Illinois University

Inhibition of T-Cell Function and ProliferationThe dark side of the synapse

Page 101: James S. Welsh, MS, MD  Northern Illinois University

Immunological Checkpoints Negative feedback inhibitors Nature’s counterbalance to immune

activation pathwaysLAG-3TIM-3CTLA-4B7-H3PD-1

Needed to avoid autoimmune disease

Page 102: James S. Welsh, MS, MD  Northern Illinois University
Page 103: James S. Welsh, MS, MD  Northern Illinois University

Tumor cells themselves can inactivate T cells!!!

Page 104: James S. Welsh, MS, MD  Northern Illinois University
Page 105: James S. Welsh, MS, MD  Northern Illinois University
Page 106: James S. Welsh, MS, MD  Northern Illinois University
Page 107: James S. Welsh, MS, MD  Northern Illinois University

Checkpoint molecules Activating: CD28 OX40 GITR CD137 CD27 HVEM

Inhibiting: CTLA-4 PD-1 TIM-3 LAG-3 VISTA BTLA

Page 108: James S. Welsh, MS, MD  Northern Illinois University

Tumors seem pretty “smart”Can we outsmart them?

Page 109: James S. Welsh, MS, MD  Northern Illinois University
Page 110: James S. Welsh, MS, MD  Northern Illinois University
Page 111: James S. Welsh, MS, MD  Northern Illinois University

Anti-CTLA4 therapy idiosyncrasies

Delayed kinetics (compared to chemotherapy)

Responses (when they occur) are often quite durable

Immune-related adverse effects

Page 112: James S. Welsh, MS, MD  Northern Illinois University

Checkpoint agents currently approved or under

development Ipilimumab

Fully human IgG1k monoclonal antibody against CTLA-4

T1/2 = 12-14 days Tremilimumab

Fully human IgG2 monoclonal antibody against CTLA-4

T1/2 = 22 days Nivolumab – Fully human IgG4 monoclonal

antibody against PD-1 Monoclonal antibodies against PD-L1

Page 113: James S. Welsh, MS, MD  Northern Illinois University
Page 114: James S. Welsh, MS, MD  Northern Illinois University
Page 115: James S. Welsh, MS, MD  Northern Illinois University

Cancer Immunotherapy II Ipilimumab (Yervoy) – monoclonal antibody against

CTLA-4 Nivolumab – monoclonal antibody against PD-1 Monoclonal antibodies against PD-L1 Denileukin diftitox (Ontak) Sipuleucel-T (Provenge) - Dendritic cell-based

immunotherapy Cell-based autologous immune enhancement

therapy (AIET) Anti-CD25 mAbs: daclizumab and basiliximab Imiquimod topical cream

Page 116: James S. Welsh, MS, MD  Northern Illinois University

Conclusions The abscopal effect suggests that the immune system

can sometimes turn the tables on cancer and gain the upper hand

Astonishing observations in:Contagious cancersTransplanted cancersNormal, ectopic and surrogate pregnanciesMolar pregnancies and choriocarcinoma

Provide intriguing insights about interactions of the immune system and cancer.

Exploitation of our new understanding of tumor immunobiology might allow Science magazine’s “2013 Breakthrough of the Year” to fulfill its promise

Page 117: James S. Welsh, MS, MD  Northern Illinois University
Page 118: James S. Welsh, MS, MD  Northern Illinois University
Page 119: James S. Welsh, MS, MD  Northern Illinois University

Could low-dose total body irradiation be a means of overcoming the cancer’s

ability to evade the immune system?

Tumors escape from immune recognition in several ways…

But - the immune escape is not necessarily irreversible

Total body irradiation MIGHT selectively deplete Treg cells while boosting T effector cells, thereby shifting the balance of power in favor of the cancer-killing arm (?)

Page 120: James S. Welsh, MS, MD  Northern Illinois University
Page 121: James S. Welsh, MS, MD  Northern Illinois University
Page 122: James S. Welsh, MS, MD  Northern Illinois University
Page 123: James S. Welsh, MS, MD  Northern Illinois University
Page 124: James S. Welsh, MS, MD  Northern Illinois University

Tumor cells have several other tricks…

Page 125: James S. Welsh, MS, MD  Northern Illinois University